The estimated Net Worth of Manuel Aivado is at least $1.18 Million dollars as of 6 June 2018. Manuel Aivado owns over 1,000 units of Aileron Therapeutics Inc stock worth over $2,880 and over the last 7 years he sold ALRN stock worth over $0. In addition, he makes $1,178,060 as President, Chief Executive Officer, and Director at Aileron Therapeutics Inc.
Manuel has made over 1 trades of the Aileron Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of ALRN stock worth $5,610 on 6 June 2018.
The largest trade he's ever made was buying 1,000 units of Aileron Therapeutics Inc stock on 6 June 2018 worth over $5,610. On average, Manuel trades about 125 units every 0 days since 2017. As of 6 June 2018 he still owns at least 1,000 units of Aileron Therapeutics Inc stock.
You can see the complete history of Manuel Aivado stock trades at the bottom of the page.
Dr. Manuel C. Aivado M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Aivado served as our senior vice president, chief medical officer since September 2014. From March 2012 to September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 to March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. Dr. Aivado has also served as an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany. Aivado is qualified to serve on our board of directors due to his service as our president and chief executive officer, his previous role as our chief medical officer, and his extensive knowledge of our company and significant background in pharmaceutical research and development.
As the President, Chief Executive Officer, and Director of Aileron Therapeutics Inc, the total compensation of Manuel Aivado at Aileron Therapeutics Inc is $1,178,060. There are no executives at Aileron Therapeutics Inc getting paid more.
Manuel Aivado is 49, he's been the President, Chief Executive Officer, and Director of Aileron Therapeutics Inc since 2018. There are 10 older and 3 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.
Manuel's mailing address filed with the SEC is C/O AILERON THERAPEUTICS, INC, 12407 N. MOPAC EXPY. SUITE 250 #390, AUSTIN, TX, 78758.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag..., and Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: